Shenzhen Bioeasy Biotechnology Co., Ltd.
SZSE:300942.SZ
11.43 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 224.249 | 254.106 | 686.897 | 597.54 | 258.456 | 239.178 | 204.933 | 137.888 | 87.047 |
| Cost of Revenue
| 65.867 | 127.232 | 298.762 | 169.51 | 63.668 | 65.86 | 64.79 | 33.797 | 22.095 |
| Gross Profit
| 158.382 | 126.874 | 388.136 | 428.029 | 194.787 | 173.318 | 140.143 | 104.091 | 64.952 |
| Gross Profit Ratio
| 0.706 | 0.499 | 0.565 | 0.716 | 0.754 | 0.725 | 0.684 | 0.755 | 0.746 |
| Reseach & Development Expenses
| 40.452 | 53.403 | 111.418 | 72.432 | 40.463 | 33.685 | 24.421 | 23.956 | 16.905 |
| General & Administrative Expenses
| 12.941 | 23.764 | 30.154 | 19.2 | 19.719 | -31.637 | -24.931 | -17.837 | 14.558 |
| Selling & Marketing Expenses
| 22.232 | 28.953 | 58.905 | 48.08 | 32.236 | 34.368 | 26.309 | 23.363 | 15.865 |
| SG&A
| 35.173 | 52.717 | 89.059 | 67.28 | 51.955 | 2.731 | 1.378 | 5.525 | 30.423 |
| Other Expenses
| 61.792 | 196.315 | -3.221 | -0.238 | -1.162 | -2.127 | -2.203 | -0.941 | 10.527 |
| Operating Expenses
| 137.417 | 302.175 | 250.431 | 160.081 | 102.245 | 75.412 | 56.186 | 58.4 | 48.212 |
| Operating Income
| 20.965 | -115.179 | 98.107 | 268.277 | 75.105 | 105.238 | 84.8 | 44.459 | 16.48 |
| Operating Income Ratio
| 0.093 | -0.453 | 0.143 | 0.449 | 0.291 | 0.44 | 0.414 | 0.322 | 0.189 |
| Total Other Income Expenses Net
| -1.276 | -7.748 | -3.221 | -0.238 | -1.162 | 28.036 | -0.12 | -0.344 | 10.527 |
| Income Before Tax
| 19.689 | -122.927 | 94.886 | 268.04 | 73.943 | 106.038 | 84.679 | 44.115 | 27.006 |
| Income Before Tax Ratio
| 0.088 | -0.484 | 0.138 | 0.449 | 0.286 | 0.443 | 0.413 | 0.32 | 0.31 |
| Income Tax Expense
| 3.07 | 7.185 | 12.222 | 31.57 | 8.494 | 13.749 | 10.766 | 4.849 | 3.586 |
| Net Income
| 17.117 | -184.908 | 82.965 | 236.507 | 65.445 | 92.308 | 73.937 | 39.293 | 23.439 |
| Net Income Ratio
| 0.076 | -0.728 | 0.121 | 0.396 | 0.253 | 0.386 | 0.361 | 0.285 | 0.269 |
| EPS
| 0.04 | -0.46 | 0.21 | 0.59 | 0.16 | 0.23 | 0.75 | 0.54 | 2.34 |
| EPS Diluted
| 0.04 | -0.46 | 0.21 | 0.59 | 0.16 | 0.23 | 0.75 | 0.54 | 2.34 |
| EBITDA
| 59.654 | -133.69 | 129.33 | 300.868 | 79.829 | 113.437 | 91.627 | 51.078 | 20.227 |
| EBITDA Ratio
| 0.266 | -0.526 | 0.188 | 0.504 | 0.309 | 0.474 | 0.447 | 0.37 | 0.232 |